That is a big market -- the diabetic market is huge. It's a good thing, if there's a new indication (for the drug). But I'm not buying the stock on the basis of this.
It's true it's a great drug and everything, but it's not enough to pick up a whole company.
We think there could be positive pipeline news over the near term.
They've been in a slump and they remain so.
